#United States #New York #Faruqi & Faruqi #Josh Wilson #Sarepta Therapeutics

Investigation of Sarepta Therapeutics by Faruqi & Faruqi

Introduction
Sarepta Therapeutics, Inc. is under scrutiny from the prominent national securities law firm Faruqi & Faruqi, LLP. The firm is conducting an investigation into potential claims arising from losses suffered by investors. Those who have seen losses exceeding $100,000 between June 22, 2023, and June 24, 2025, are particularly urged to reach out for insights on their legal rights and the possibility of joining a class action lawsuit.

Background on Sarepta Therapeutics

Sarepta Therapeutics specializes in developing innovative therapies for rare diseases, with a focus on genetic medicine, particularly mutations causing Duchenne muscular dystrophy (DMD). However, recent safety updates regarding one of its leading products, ELEVIDYS, have raised significant concerns. Allegations suggest that the company's management may have made misleading statements about the safety and efficacy of its clinical trials, potentially violating federal securities laws.

Allegations Against Sarepta

The ongoing inquiry centers on several serious claims:
1. Safety Risks: The allegation asserts that ELEVIDYS poses considerable safety risks that were not transparently communicated to investors.
2. Inadequate Trial Protocols: It is claimed that the trial regimens were insufficient for detecting severe side effects, leading to fatal outcomes for some patients.
3. Regulatory Scrutiny: The severity of adverse events from ELEVIDYS treatment prompted Sarepta to halt recruitment into clinical trials, drawing the attention of regulatory bodies and elevating the risk around the therapy's current and future approvals.
4. Misleading Statements: The firm argues that the company’s executives made unwarranted positive statements regarding the therapy's safety and effectiveness without a reasonable basis for such claims.

Timeline of Events

The situation escalated dramatically over a series of unfortunate events:

• - On March 18, 2025, Sarepta confirmed a patient's death linked to ELEVIDYS, resulting in a significant drop of approximately 27% in their share price.
• - Following this, on April 4, 2025, the company disclosed requests from EU authorities to review the death and announced a suspension of recruitment, which further impacted their stock prices.
• - A second death was reported on June 15, 2025, associated with acute liver failure after ELEVIDYS treatment. This announcement led to a staggering 42% drop in share prices, indicating severe investor reactions to the news.
• - Lastly, the FDA issued a Safety Communication on June 24, 2025, informing that there were two reported deaths associated with the therapy, prompting investor concerns and another drop in stock prices.

Importance of Acting Quickly

The importance of swift action cannot be overstated. The deadline to apply for the role of lead plaintiff in the federal securities class action against Sarepta is August 25, 2025. Investors who choose to liaise with Faruqi & Faruqi will be able to gain legal counsel and potentially recover losses incurred due to misleading information. It is critical for affected investors to consider their options and secure their rights as members of the putative class.

Consultation and Further Information

Faruqi & Faruqi continues to encourage any party with information concerning Sarepta's conduct to come forward. This includes whistleblowers, current or former employees, and shareholders. Stakeholders can find additional information on how to partake in the class action at Faruqi’s official website.

Conclusion

The investigation into Sarepta Therapeutics highlights key issues of accountability and transparency that are paramount in the pharmaceutical industry. As this developing story unfolds, investors must remain vigilant and informed. Those affected should not hesitate to consult legal experts to explore their options thoroughly.